Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2013

Open Access 01-12-2013 | Study protocol

Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial

Authors: Roxana C Bucur, Lauren S Reid, Celeste J Hamilton, Steven R Cummings, Sophie A Jamal

Published in: Trials | Issue 1/2013

Login to get access

Abstract

Background

Organic nitrates uncouple bone turnover, improve bone mineral density, and improve trabecular and cortical components of bone. These changes in turnover, strength and geometry may translate into an important reduction in fractures. However, before proceeding with a large fracture trial, there is a need to identify the nitrate formulation that has both the greatest efficacy (with regards to bone turnover markers) and gives the fewest headaches. Ascertaining which nitrate formulation this may be is the purpose of the current study.

Methods and design

This will be an open-label randomized, controlled trial conducted at Women’s College Hospital comparing five formulations of nitrates for their effects on bone turnover markers and headache. We will recruit postmenopausal women age 50 years or older with no contraindications to nitroglycerin. Our trial will consist of a run-in phase and a treatment phase. We will enroll 420 women in the run-in phase, each to receive all of the 5 potential treatments in random order for 2 days, each with a 2-day washout period between treatments. Those who tolerate all formulations will enter the 12-week treatment phase and be randomly assigned to one of five groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg of the sublingual tablet, a 20 mg tablet of isosorbide mononitrate, a 160 mg nitroglycerin transdermal patch (used for 8 h), and 15 mg of nitroglycerin ointment as used in a previous trial by our group. We will continue enrolment until we have randomized 210 women or 35 women per group. Concentrations of bone formation (bone-specific alkaline phosphatase and procollagen type I N-terminal propeptide) and bone resorption (C-telopeptides of collagen crosslinks and N-terminal crosslinks of collagen) agents will be measured in samples taken at study entry (the start of the run in phase) and 12 weeks. Subjects will record the frequency and severity of headaches daily during the run-in phase and then monthly after that. We will use the ‘multiple comparisons with the best’ approach for data analyses, as this strategy allows practical considerations of ease of use and tolerability to guide selection of the preparation for future studies.

Discussion

Data from this protocol will be used to develop a randomized, controlled trial of nitrates to prevent osteoporotic fractures.

Trial registration

ClinicalTrials.gov Identifier: NCT01387672. Controlled-Trials.com: ISRCTN08860742.
Appendix
Available only for authorised users
Literature
1.
Jamal SA, Hamilton CJ, Eastell R, Cummings SR: Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA. 2011, 305: 800-807. 10.1001/jama.2011.176.CrossRefPubMed
2.
Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ: Epidemiology of osteoporosis and osteoporotic fracture. Epidemiol Rev. 1985, 7: 178-208.PubMed
3.
Hawker G: Chapter 1: Epidemiology of arthritis and osteoporosis. Patterns of Health Care in Ontario: Arthritis and Related Conditions. Edited by: Badley EM, Williams JI. 1998, Toronto, Canada: Institute of Clinical Evaluative Sciences
4.
Jaglal S: Chapter 8: osteoporotic fractures: incidence and impact. Patterns of Health Care in Ontario: Arthritis and Related Conditions. Edited by: Bradley EM, Williams JI. 1998, Toronto, Canada: Institute of Clinical Evaluative Sciences
5.
Melton LJI, Cooper C: Magnitude and impact of osteoporosis and fractures. Osteoporosis. Edited by: Marcus R, Feldman D, Kelsey J. 2001, San Diego CA: Academic Press, 1: 557-567. 2CrossRef
6.
Gullberg B, Johnell O, Kanis JA: World-wide projections for hip fracture. Osteoporos Int. 1997, 7: 407-413. 10.1007/PL00004148.CrossRefPubMed
7.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361: 756-765. 10.1056/NEJMoa0809493.CrossRefPubMed
8.
Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Eckert S, Black D: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000, 8: 1318-1321.CrossRef
9.
Cryer R, Bauer DC: Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc. 2002, 77: 1031-1043. 10.4065/77.10.1031.CrossRefPubMed
10.
Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D: Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000, 160: 517-525. 10.1001/archinte.160.4.517.CrossRefPubMed
11.
Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR: Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007, 22: 503-508. 10.1359/jbmr.070112.CrossRefPubMed
12.
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010, 25: 2267-2294. 10.1002/jbmr.253.CrossRefPubMed
13.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
14.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281: 2189-2197. 10.1001/jama.281.23.2189.CrossRefPubMed
15.
Cummings SR, Cosman F, Jamal SA: Osteoporosis. An evidenced-based guide to prevention and management. Women’s Health Series. Edited by: Charney P. 2002, Philadelphia, PA: American College of Physicians, 161-164.
16.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344: 1434-1441. 10.1056/NEJM200105103441904.CrossRefPubMed
17.
Kawai M, Modder UI, Khosla S, Rosen CJ: Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov. 2011, 10: 141-156. 10.1038/nrd3299.CrossRefPubMedPubMedCentral
18.
Reginster JY: Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2011, 71: 65-78. 10.2165/11587570-000000000-00000.CrossRefPubMed
19.
Cummings SR: A 55-year-old woman with osteopenia. JAMA. 2006, 296: 2601-2610. 10.1001/jama.296.21.2601.CrossRefPubMed
20.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996, 348: 1535-1541. 10.1016/S0140-6736(96)07088-2.CrossRefPubMed
21.
Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998, 280: 2077-2082. 10.1001/jama.280.24.2077.CrossRefPubMed
22.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999, 282: 1344-1352. 10.1001/jama.282.14.1344.CrossRefPubMed
23.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356: 1809-1822. 10.1056/NEJMoa067312.CrossRefPubMed
24.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999, 282: 637-645. 10.1001/jama.282.7.637.CrossRefPubMed
25.
26.
Chae HJ, Park RK, Chung HT, Kang JS, Kim MS, Choi DY, Bang BG, Kim HR: Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol. 1997, 49: 897-902. 10.1111/j.2042-7158.1997.tb06132.x.CrossRefPubMed
27.
Evans CH, Stefanovic-Racic M, Lancaster J: Nitric oxide and its role in orthopaedic disease. Clin Orthop. 1995, 312: 275-294.PubMed
28.
Feelisch M: Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J. 1993, 14: 123-132.PubMed
29.
Ralston SH: The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas!. Br J Rheumatol. 1997, 36: 831-838. 10.1093/rheumatology/36.8.831.CrossRefPubMed
30.
Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, MacIntyre I: Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA. 1995, 92: 2954-2958. 10.1073/pnas.92.7.2954.CrossRefPubMedPubMedCentral
31.
Collin-Osdoby P, Nickols GA, Osdoby P: Bone cell function, regulation and communication: a role for nitric oxide. J Cell Biochem. 1995, 57: 399-408. 10.1002/jcb.240570305.CrossRefPubMed
32.
Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE: Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest. 1994, 93: 1465-1472. 10.1172/JCI117124.CrossRefPubMedPubMedCentral
33.
MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, Hecker M, Vane JR: Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci USA. 1991, 88: 2936-2940. 10.1073/pnas.88.7.2936.CrossRefPubMedPubMedCentral
34.
Kasten TP, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko TP, Settle SL, Currie MG, Nickols GA: Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci USA. 1994, 91: 3569-3573. 10.1073/pnas.91.9.3569.CrossRefPubMedPubMedCentral
35.
Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N: Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995, 10: 1040-1049.CrossRefPubMed
36.
Collin-Osdoby P, Li L, Rothe L, Anderson F, Kirsch D, Oursler MJ, Osdoby P: Inhibition of avian osteoclast bone resorption by monoclonal antibody 121F: a mechanism involving the osteoclast free radical system. J Bone Miner Res. 1998, 13: 67-78. 10.1359/jbmr.1998.13.1.67.CrossRefPubMed
37.
Chow JW, Fox SW, Lean JM, Chambers TJ: Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res. 1998, 13: 1039-1044. 10.1359/jbmr.1998.13.6.1039.CrossRefPubMed
38.
Ake Y, Saegusa Y, Matsubara T, Mizuno K: Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci. 1994, 40: 125-137.PubMed
39.
Aguirre J, Buttery L, O’Shaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M, Huang P, MacIntyre I, Polak J: Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol. 2001, 158: 247-257. 10.1016/S0002-9440(10)63963-6.CrossRefPubMedPubMedCentral
40.
Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, Ralston SH: Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology. 2001, 142: 760-766. 10.1210/en.142.2.760.PubMed
41.
Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C: Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996, 18: 301-304. 10.1016/8756-3282(96)00005-1.CrossRefPubMed
42.
Jamal SA, Browner WS, Bauer DC, Cummings SR: Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998, 13: 1755-1759. 10.1359/jbmr.1998.13.11.1755.CrossRefPubMed
43.
Abshagen A, Sporl-Radun S: First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol. 1981, 19: 423-429. 10.1007/BF00548586.CrossRefPubMed
44.
Thadani U: Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther. 1997, 10: 734-742.CrossRef
45.
Wimalawansa SJ, Chapa T, Wimalawansa S, Fang L, Yallampalli C: Dose and Frequency Effects of Nitric Oxide Donor Nitroglycerine on Bone. 1997, Minneapolis, MN, USA: Seventy-ninth Annual Meeting of the Endocrine Society, abstract P3-248
46.
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995, 332: 767-773. 10.1056/NEJM199503233321202.CrossRefPubMed
47.
Rejnmark L, Vestergaard P, Mosekilde L: Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res. 2006, 21: 1811-1817. 10.1359/jbmr.060804.CrossRefPubMed
48.
Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG, Rejnmark L, de Boer A, Vestergaard P, de Vries F: Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab. 2010, 95: 1924-1931. 10.1210/jc.2009-2342.CrossRefPubMedPubMedCentral
49.
Jamal SA, Cummings SR, Hawker GA: The effects of isosorbide mononitrate on bone turnover: a randomized controlled trial. J Bone Miner Res. 2004, 19: 1512-1517. 10.1359/JBMR.040716.CrossRefPubMed
50.
Fung H: Pharmacokinetics of nitroglycerin and long-acting nitrate esters. Am J Med. 1983, 12: 13-20.CrossRef
51.
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002, 87: 1586-1592. 10.1210/jc.87.4.1586.CrossRefPubMed
52.
Looker AC, Bauer DC, Chesnut CH, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH: Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000, 11: 467-480. 10.1007/s001980070088.CrossRefPubMed
53.
Wimalawansa SJ: Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res. 2000, 15: 2240-2244. 10.1359/jbmr.2000.15.11.2240.CrossRefPubMed
54.
Jamal SA, Hamilton CJ, Black D, Cummings SR: The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. Trials. 2006, 7: 10-10.1186/1745-6215-7-10.CrossRefPubMedPubMedCentral
55.
Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR: Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009, 94: 3356-3364. 10.1210/jc.2008-2225.CrossRefPubMedPubMedCentral
56.
Christiansen I, Iversen HK, Olesen J: Headache characteristics during the development of tolerance to nitrates: pathophysiologic implications. Cephalagia. 2000, 20: 437-444. 10.1046/j.1468-2982.2000.00064.x.CrossRef
57.
Bogaert MG: Pharmacokinetics of organic nitrates in man: an overview. Eur Heart J. 1988, 9 (Suppl A): 33-37. 10.1093/eurheartj/9.suppl_A.33.CrossRefPubMed
58.
Shively M, Riegel B: Effect of nitroglycerin ointment placement on headache and flushing in healthy subjects. Int J Nurs Stud. 1991, 28: 153-161. 10.1016/0020-7489(91)90005-N.CrossRefPubMed
59.
Riegel B, Heywood G, Jackson W, Kennedy A: Effect of nitroglycerin ointment placement on the severity of headache and flushing in patients with cardiac disease. Heart Lung. 1988, 17: 426-431.PubMed
60.
Block G, Hartman AM, Naughton D: A reduced dietary questionnaire: development and validation. Epidemiol. 1990, 1: 58-64. 10.1097/00001648-199001000-00013.CrossRef
61.
Brown JP, Josse RG: Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002, 167 (Suppl): S1-S34.PubMedPubMedCentral
62.
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD: Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010, 182: 1864-1873.CrossRefPubMedPubMedCentral
63.
Wallin J, Sjovall J: Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther. 1981, 3: 450-452.PubMed
64.
Jamal SA: The Effects of Isosorbide Mononitrate on Markers of Bone Turnover: A Randomized Double Blind Placebo Controlled Trial. 2003, University of Toronto, Toronto, Canada: Health Policy Management and Evaluation, PhD thesis
65.
Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA: International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011, 49: 1271-1274.CrossRefPubMed
66.
Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, Eastell R: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res. 2010, 25: 463-471. 10.1359/jbmr.090830.CrossRefPubMed
67.
Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM: Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006, 21: 292-299.CrossRefPubMed
68.
Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J: Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone. 2004, 34: 344-351. 10.1016/j.bone.2003.10.004.CrossRefPubMed
69.
Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM: Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006, 91: 1370-1375. 10.1210/jc.2005-1712.CrossRefPubMed
70.
Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003, 18: 1051-1056. 10.1359/jbmr.2003.18.6.1051.CrossRefPubMed
71.
72.
Hsu J: Multiple Comparisons: Theory and Methods. 1996, London, UK: Chapman and HallCrossRef
73.
Cummings SR, Melton J: Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002, 359: 1761-1767. 10.1016/S0140-6736(02)08657-9.CrossRefPubMed
74.
Clowes JA, Eastell R: Markers of bone turnover and laboratory evaluation of secondary osteoporosis. Osteoporosis: An Evidence-Based Guide to Prevention and Management. Edited by: Cummings SR, Cosman F, Jamal SA. 2002, Philadelphia, PA: American College of Physicians, 59-82.
75.
Delmas PD: Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int. 2000, 11 (Suppl 6): S66-S76.CrossRefPubMed
76.
Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000, 11 (Suppl 6): S2-S17.CrossRefPubMed
77.
Hannon R, Blumsohn A, Naylor K, Eastell R: Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998, 13: 1124-1133. 10.1359/jbmr.1998.13.7.1124.CrossRefPubMed
78.
Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R: Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999, 37: 846-857. 10.1097/00005650-199909000-00002.CrossRefPubMed
Metadata
Title
Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial
Authors
Roxana C Bucur
Lauren S Reid
Celeste J Hamilton
Steven R Cummings
Sophie A Jamal
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Trials / Issue 1/2013
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-14-284

Other articles of this Issue 1/2013

Trials 1/2013 Go to the issue

Study protocol

A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial

Study protocol

The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial

Study protocol

Assessing the effectiveness and cost effectiveness of subcutaneous nerve stimulation in patients with predominant back pain due to failed back surgery syndrome (SubQStim study): study protocol for a multicenter randomized controlled trial

Study protocol

Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial)

Study protocol

Task-oriented training with computer gaming in people with rheumatoid arthritis or osteoarthritis of the hand: study protocol of a randomized controlled pilot trial

Study protocol

Morning light therapy for juvenile depression and severe mood dysregulation: study protocol for a randomized controlled trial